Indications
Senstend is indicated for the treatment of primary premature ejaculation in adult men.
Composition
- Active substance
- lidocaine, prilocaine
- International name (INN)
- lidocaine;prilocaine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Senstend
- Active substance
- lidocaine, prilocaine
- ATC code
- N01BB20
- Group
- Nervous system
- Therapeutic area
- Premature Ejaculation
- Marketing authorisation holder
- Plethora Pharma Solutions Limited
- Status
- Withdrawn
- EU authorisation